Literature DB >> 8719514

Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.

I Cropley1, G Douce, M Roberts, S Chatfield, M Pizza, I Marsili, R Rappuoli, G Dougan.   

Abstract

The effect of formaldehyde treatment on the mucosal and systemic immunogenicity of the genetically detoxified pertussis toxin (PT-9K/129G) was investigated. Groups of BALB/c were immunized intranasally (i.n.) or subcutaneously (s.c.) with untreated, lightly formaldehyde treated (LFT) or heavily formaldehyde treated (HFT) recombinant pertussis toxin (PT) mutant, PT-9K/129G. Intranasal immunization with native PT-9K/ 129G induced significant levels of anti-toxin antibodies in serum and IgA anti-toxin responses in nasal and lung lavages of these mice. Similar local and systemic responses were observed following intransal immunization with LFT toxin. However, i.n. immunization with HFT toxin failed to induce a local IgA response and elicited a much diminished anti-toxin response in the serum. In contrast, the total antibody response following s.c. immunization was not significantly affected. In addition, i.n. immunization with native PT-9K/129G induced low but detectable levels of toxin neutralizing antibodies in the serum. These results show that native PT-9K/129G protein acts as a mucosal immunogen in mice and that this activity is greatly diminished by HFT of the protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719514     DOI: 10.1016/0264-410x(95)00134-m

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Mutational analysis of the Helicobacter pylori vacuolating toxin amino terminus: identification of amino acids essential for cellular vacuolation.

Authors:  D Ye; S R Blanke
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.

Authors:  H Genth; J Selzer; C Busch; J Dumbach; F Hofmann; K Aktories; I Just
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 3.  The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.

Authors:  G Dougan; M Ghaem-Maghami; D Pickard; G Frankel; G Douce; S Clare; S Dunstan; C Simmons
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

4.  The identification of plant lectins with mucosal adjuvant activity.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

5.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.

Authors:  B G Stiles; A R Garza; R G Ulrich; J W Boles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Detoxification of the Helicobacter pylori cytotoxin.

Authors:  R Manetti; P Massari; M Marchetti; C Magagnoli; S Nuti; P Lupetti; P Ghiara; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

9.  Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.

Authors:  S J Ward; G Douce; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

10.  Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.

Authors:  Ignazio Castagliuolo; Marina Sardina; Paola Brun; Chiara DeRos; Cristina Mastrotto; Laura Lovato; Giorgio Palù
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.